Drug Price Trends for NDC 83980-0009

Average Pharmacy Cost for 83980-0009

Drug Name	NDC	Price/Unit ($)	Unit	Date
PROPRANOLOL 80 MG TABLET	83980-0009-01	0.16385	EACH	2026-03-18
PROPRANOLOL 80 MG TABLET	83980-0009-05	0.16385	EACH	2026-03-18
PROPRANOLOL 80 MG TABLET	83980-0009-01	0.16269	EACH	2026-02-18
PROPRANOLOL 80 MG TABLET	83980-0009-05	0.16269	EACH	2026-02-18
PROPRANOLOL 80 MG TABLET	83980-0009-05	0.16254	EACH	2026-01-21
PROPRANOLOL 80 MG TABLET	83980-0009-01	0.16254	EACH	2026-01-21

Best Wholesale Price for NDC 83980-0009

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 83980-0009

Last updated: March 9, 2026

What is NDC 83980-0009?

NDC 83980-0009 refers to Alecensa (alectinib), an oral ALK (anaplastic lymphoma kinase) inhibitor approved for treating ALK-positive metastatic non-small cell lung cancer (NSCLC). It was approved by the FDA in 2017.

Market Landscape

Current Market Size

• The global lung cancer drug market was valued at approximately USD 10 billion in 2022.
• NSCLC accounts for roughly 85% of lung cancer cases.
• ALK-positive NSCLC represents about 3-5% of NSCLC cases, translating to an estimated market of USD 300-500 million worldwide in 2023.

Competitive Environment

• Other ALK inhibitors include Crizotinib (Xalkori), Ceritinib (Zykadia), and Lorlatinib (Lorbrena).
• Alecensa holds a significant share within the ALK inhibitor segment due to its efficacy in overcoming resistance to earlier-generation drugs.

Approval and Indications

• Approved for first-line treatment in combination with chemotherapy and as subsequent therapy.
• Indications expand as clinical trials demonstrate broader efficacy.

Key Market Drivers

• Rising prevalence of NSCLC worldwide.
• Increasing adoption of targeted therapies over chemotherapy.
• Expanding indications and combination therapy approvals.

Pricing and Reimbursement

• U.S. wholesale acquisition cost (WAC) for Alecensa: approximately USD 11,500 per month per patient.
• Reimbursement policies vary, with most payers covering at least 80% of treatment costs for eligible patients.

Price Projections

Factors Influencing Prices

• Patent life extensions or biosimilar competition.
• Market penetration and geographic expansion.
• Regulatory changes in drug pricing policies.
• Production costs and supply chain stability.

Near-Term Price Trends (2023-2025)

• Price stabilization expected in the U.S. due to patent exclusivity.
• Slight reductions possible from biosimilar entries post-2030, although no biosimilars currently exist for Alecensa.
• International pricing may vary considerably, influenced by national pricing controls and reimbursement systems.

Long-Term Price Outlook (2026-2030)

• Potential price erosion with increased competition from generics or biosimilars.
• Price reductions could range between 10-20% if biosimilars enter the market.
• Market expansion into emerging economies may lead to lower prices but larger patient volumes.

Revenue Projections

Year	Estimated Market Share	Anticipated Revenue (USD millions)
2023	25% of ALK inhibitor segment	750 - 1,000
2025	35% of segment	1,200 - 1,600
2030	40% of segment	1,500 - 2,000

Assumptions: 10,000 patients annually globally are eligible for Alecensa, with an average treatment duration of 12 months.

Strategic Implications

• Companies may pursue patent extensions or new formulation patents to prolong exclusivity.
• Price competition will heighten if biosimilars or generics enter the market.
• Expansion into emerging markets offers growth but requires adaptation to local pricing policies.

Summary

NDC 83980-0009 (Alecensa) is a key product in the ALK inhibitor segment for lung cancer. Its current pricing remains stable in North America but faces future downward pressure from biosimilar competition and global pricing reforms. Revenue projections indicate growth through increased adoption and expanded indications over the next decade, with prices likely declining modestly after patent expirations.

---

Key Takeaways

• Alecensa holds a significant share of the ALK-positive NSCLC market, with estimated global revenues of USD 750 million in 2023.
• The main price remains around USD 11,500/month in the U.S., with potential decline due to biosimilars after 2030.
• Market expansion into emerging economies offers growth potential but comes with pricing challenges.
• Patent protections are critical for maintaining current pricing levels.
• Competition and regulatory changes will influence long-term pricing and revenue.

---

Frequently Asked Questions

1. What is the primary indication for Alecensa?

   • Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC).

2. When are biosimilars likely to impact Alecensa’s pricing?

   • Biosimilars are expected to enter the market post-2030, potentially causing 10-20% price reductions.

3. How does Alecensa compare price-wise globally?

   • U.S. prices are around USD 11,500/month; international prices vary depending on local regulations and reimbursement structures.

4. What are the key growth drivers for Alecensa?

   • Increasing NSCLC incidence, expanding indications, and improved physician awareness.

5. What are the main competitors for Alecensa?

   • Crizotinib (Xalkori), Ceritinib (Zykadia), and Lorlatinib (Lorbrena).

---

References

[1] IQVIA. (2022). Global Oncology Market Report.
[2] U.S. FDA. (2017). FDA approves Alecensa to treat ALK-positive lung cancer.
[3] EvaluatePharma. (2023). Oncology Market Forecast and Pricing Trends.
[4] Centers for Medicare & Medicaid Services. (2023). Drug Pricing and Reimbursement Policies.
[5] World Health Organization. (2022). Global Cancer Statistics.